management interviews
Jump to
50 Results Found
  • There is high pricing pressure on manufacturers: DRL Feb 26, 2018 02:42 PM IST

    There is high pricing pressure on manufacturers: DRL

    This weekend was abuzz with the pharma industry bigwigs who had gathered at the 15th edition of the Bio Asia Summit. CNBC-TV18’s Ekta Batra was there as well and she caught up with Satish Reddy, Chairman of Dr Reddy's to talk about the pricing pressure and the way ahead.

  • FM's universal healthcare proposal a step in right direction: DRL Feb 08, 2018 01:48 PM IST

    FM's universal healthcare proposal a step in right direction: DRL

    In an exclusive conversation with CNBC-TV18's Nitya Balakrishnan, Saumen Chakraborty of DRL adds that the company will maintain its capex target of Rs 1,000 crore for FY19, and it will focus on biological research and development (R&D).

  • Hope to resolve Srikakulam with US FDA soon, says DRL Jan 29, 2018 08:37 AM IST

    Hope to resolve Srikakulam with US FDA soon, says DRL

    From the pharmaceutical space, Dr Reddys Laboratories (DRL) reported a mixed set of earnings this quarter. In an interview to CNBC-TV18, Saumen Chakraborty, CFO of DRL discussed the company's Q3 performance.

  • TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study Dec 08, 2017 12:19 PM IST

    TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study

    Ajanta Pharma retains the tag of fastest wealth creator for the third time in a row and Asian Paints is the most consistent wealth creator, said the wealth creation study

  • Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO Oct 07, 2017 02:55 PM IST

    Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO

    Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.

  • New draft pharma policy will reduce risks like generalisation of mkt: JM Financial Sep 15, 2017 04:04 PM IST

    New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

    In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.

  • Preparing for GST implementation for past few months: DRL's Chakraborty Jun 30, 2017 11:30 AM IST

    Preparing for GST implementation for past few months: DRL's Chakraborty

    In the latest, CNBC-TV18's Ekta Batra and Vikas Dandekar caught up with Saumen Chakraborty, CFO of Dr Reddy's Laboratories (DRL) and asked him amongst other things, if pharmaceutical companies like DRL will feel the jitters once GST is rolled out.

  • Expect to see 18-20% growth for FY18: TCI Express Jun 01, 2017 04:21 PM IST

    Expect to see 18-20% growth for FY18: TCI Express

    In an interview to CNBC-TV18, Chander Agarwal, MD & CEO, TCI Express spoke about the results and his outlook for the company.

  • Govt needs to be a strong enabler in pharma sector: Experts Feb 07, 2017 10:14 PM IST

    Govt needs to be a strong enabler in pharma sector: Experts

    Shereen Bhan speaks with top bosses from the pharma sector along with KT Rama Rao, Minister of IT, Telangana at Bioasia 2017 to discuss way forward for pharma sector in making India healthier.

  • Expect US FDA approvals to pick going forward: Dr Reddy's Feb 06, 2017 02:00 PM IST

    Expect US FDA approvals to pick going forward: Dr Reddy's

    Saumen Chakraborty, CFO of Dr Reddy's is confident of getting back on to the growth path starting FY18 on the back of more than 15 significant launches and approvals that will help the pharma major make a comeback.

  • Q4 to be lean qtr for US biz due to delayed launches: Dr Reddy's Feb 06, 2017 11:17 AM IST

    Q4 to be lean qtr for US biz due to delayed launches: Dr Reddy's

    The pharma major reported third quarter earnings on Saturday. While revenues declined, the drop was in-line with expectations and was overall an operationally strong quarter.

  • No scope of US intervention in Indian pharma cos: Wockhardt Jan 12, 2017 01:07 PM IST

    No scope of US intervention in Indian pharma cos: Wockhardt

    Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.

  • New launches in H2FY17 will boost growth: Dr Reddy's Jul 27, 2016 03:44 PM IST

    New launches in H2FY17 will boost growth: Dr Reddy's

    The fall in revenue and profits in the first quarter was due to lack of launches in the US, says Saumen Chakraborty, CFO of Dr Reddy‘s. The company launched its first product in the US in July.

  • Indian assets doing well; hopeful of few launches in US: DRL Jul 26, 2016 09:37 PM IST

    Indian assets doing well; hopeful of few launches in US: DRL

    For the first quarter ended June, Dr Reddy‘s Laboratories missed estimates on all counts. Revenue declined 14 percent to Rs 3,222.5 crore in the quarter ended June 2016 from Rs 3,752.2 crore in same period last year.

  • Lupin to see approvals after US FDA gives clean chit: Macquarie Jul 08, 2016 09:11 AM IST

    Lupin to see approvals after US FDA gives clean chit: Macquarie

    Of the total 18 observations, 9 from July 2015 and another 9 from March 2016 inspection, the former ones relating to equipment and warehousing have been closed. Nine observations are still outstanding for the company.

  • Hope to commercialise 4 products acquired from Teva by FY18: DRL Jun 13, 2016 02:12 PM IST

    Hope to commercialise 4 products acquired from Teva by FY18: DRL

    Saumen Chakraborty, CFO of the company told CNBC-TV18 that they hope to commercialise four out of the eight products by FY18. He said all the eight products are expected to have limited competition.

  • After DRL-Teva, expect more M&A action in pharma: Prabhudas Jun 13, 2016 09:26 AM IST

    After DRL-Teva, expect more M&A action in pharma: Prabhudas

    Pharma companies are losing market share and such deals help them,says Surajit Pal of Prabhudas Lilladher.

  • US FDA issues shouldn't be overbearing factor for pharma: Citi Jun 07, 2016 10:57 AM IST

    US FDA issues shouldn't be overbearing factor for pharma: Citi

    Executives of Dr Reddy's Laboratories and Citi tell CNBC-TV18 that the second half of 2016 should be a good one for pharma industry.

  • New launches to drive growth in second quarter: Dr Reddy's May 12, 2016 08:53 PM IST

    New launches to drive growth in second quarter: Dr Reddy's

    There are approvals pending, but not from its Srikakulam plant. But improving quality checks at pharma's plants would be a high priority, says GV Prasad, CEO, Dr Reddy‘s.

  • Regulatory issues discussed in Feb meet with US, Europe: DRL Apr 29, 2016 09:29 AM IST

    Regulatory issues discussed in Feb meet with US, Europe: DRL

    Company will continue with tie-ups for biosimilar products. These will first be launched in India and then in other markets, says Satish Reddy, Chairman of Dr Reddy‘s Lab.

  • Indian pharma cos need to step-up safeguards at plants: Handa Mar 29, 2016 09:29 PM IST

    Indian pharma cos need to step-up safeguards at plants: Handa

    In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.

  • 20% of Cipla FY17 revenues to come from US: Chirag Talati Feb 23, 2016 01:47 PM IST

    20% of Cipla FY17 revenues to come from US: Chirag Talati

    When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.

  • Board to consider buyback of equity shares on Feb 17: Dr Reddy's Feb 11, 2016 11:06 AM IST

    Board to consider buyback of equity shares on Feb 17: Dr Reddy's

    Saumen Chakraborty, President and CFO, Dr Reddy's Lab said they will be making a proposal to the board for buying back equity shares on February 17.

  • See huge opportunity in Venezuela; US supply not restricted: DRL Feb 09, 2016 08:00 PM IST

    See huge opportunity in Venezuela; US supply not restricted: DRL

    Saumen Chakraborty, CFO, Dr Reddy's, says the company has been calibrating sales in Venezuala where the market and capacity is huge.

  • Pharma cos capable of resolving FDA concern in 12-15 months:IIFL Jan 18, 2016 12:34 PM IST

    Pharma cos capable of resolving FDA concern in 12-15 months:IIFL

    Sharma, however, believes that despite the issues getting compounded by the day, most of the companies have enough capabilities to resolve them within the next 12-15 months.

Sections